多巴胺D2受体基因启动子多态性与帕金森病的关联研究

目的 探讨中国汉族人群多巴胺D2受体基因启动子多态性在帕金森病（Parkinson's disease,PD)遗传易感性中的作用。方法 采用病例－对照关联分析，聚合酶链反应－限制性片段长度多态性方法分析了123例PD患者（PD组）与124名健康成人（对照组）多巴胺D2受体基因启动子多态性。结果 PD组－141△C等位基因频率为8．5％，对照组为11．7％；两组差异无显著性（P＞0．05）；中国汉族人PD组组和对照组－141△C等位基因频率明显高于意大利南部人群，差异有显著性（P＜0．05）。结论中国汉族人群多巴胺D2受体基因启动子多态性与PD的遗传易感性无关，该多态性有明显的种族差异。     

多巴胺D3受体基因Ser-9-Gly多态性精神分裂症的关联研究

为探讨精神分裂症与多巴胺 D3受体基因 ( dopamine D3receptor gene,DRD3) Ser-9-Gly多态性是否关联。应用PCR-RFLP方法检测了广州地区汉族人群中 1 2 3例家族史阴性、1 1 3例家族史阳性精神分裂症患者、1 6 8例家族史阴性患者父母和 4 7例正常老年人中多巴胺 D3受体基因 Ser-9-Gly多态性 ,并对多巴胺 D3受体基因各等位基因及基因型与精神分裂症进行了相关分析 ,DRD3与精神分裂症、患者性别及家族史均无关联 ( P>0 .0 5 )。提示广州地区汉族人群中DRD3基因 Ser-9-Gly多态性与精神分裂症没有关联。     

GRIA2基因多态性与中国北方汉族人群精神分裂症的关联研究

目的 探讨谷氨酸离子型受体AMPA亚基2(GRIA2)基因多态性与中国北方地区汉族人群精神分裂症易感性之间的关联.方法 提取中国北方地区汉族精神分裂症患者150例(病例组)和健康志愿者160例(对照组)全血DNA,并采用iMLDR多重SNP分型技术检测GRIA2基因rs4302506、rs3813296、rs42605...     

多巴胺D2受体基因与精神分裂症和双相情感障碍关联研究的荟萃分析

遗传因素是精神分裂症(schizophrenia,SCZ)和双相情感障碍(bipolar disorder,BP)的重要致病因素,已有大量基因关联研究表明多巴胺D2受体基因与两种精神疾病可能存在风险关系,然而许多研究的结果并不一致.系统的荟萃分析可以弥补单个研究样本量小可能引起的结果偏差.经过严格筛选,本文纳入8个关于BP和49个关于SCZ的独立研究,荟萃分析多巴胺D2受体3个基因多态性(141C Del/Ins、TaqI-A、SCr311Cys)与这两种精神疾病的风险关系.结果 提示Ser311Cys的G/C多态性和SCZ发病显著关联,而TaqI-A的T/C多态性和BP发病存在显著关联(P<0.05).基因型分析结果揭示了多巴胺D2受体基因Ser311Cys携带G等位基因的基因型是SCZ的风险因素,TaqI-A的TT基因型可能是BP的风险因子而对于SCZ是保护因子.     

广州地区汉族人群多巴胺受体基因多态性

目的 探讨广州地区汉族人群多巴胺Ｄ２（ＤＲＤ２）、Ｄ５（ＤＲＤ５）受体基因的多态性分布规律。方法 用聚合酶链反应－限制性片段长度多态性和聚合酶链反应－等位基因特异性扩增技术对１４１名广州地区汉族人的ＤＲＤ２、ＤＲＤ３、ＤＲＤ５基因多态性进行了检测,并与其他人群做了比较。结果 ＤＲＤ２基因３’端非翻译区的Ｔａｑ１Ａ突变点Ａ１（ＴａｑＩ－）、Ａ２（ＴａｑＩ＋）等位基因频率分别为４８％和５２％;Ａ１Ａ１     

多巴胺D4受体和COMT基因多态性在精神分裂症患者攻击行为中的交互作用

目的:讨论多巴胺D4受体(DRD4)基因第3外显子48bp可重复序列多态性(exon Ⅲ 48 bp VNTR)和COMT val158met基因多态性及其交互作用对精神分裂症患者攻击行为的影响.方法:采用修改版外显攻击行为量表(MOAS)对301例精神分裂症患者进行分组,分为伴攻击行为组(研究组)和不伴攻击行为组(对...     

代谢型谷氨酸受体-3基因多态性和精神分裂症临床症状关联研究

目的:探讨中国汉族人群代谢型谷氨酸受体-3(mGluR3)基因多态性与偏执型精神分裂症临床症状之间的关系.方法:应用阳性与阴性症状量表(PANSS)于入院一周内评估362例偏执型精神分裂症患者的临床症状;采用DNA测序技术检测上述患者mGluR3基因单核苷酸多态性(SNP)rs274622和rs6465084的基因型;并采用卡方检验和多元线性回归分析探讨不同性别患者上述两多态性位点及其联合作用与临床症状之间的关系.结果:rs274622和rs6465084的基因型和等位基因的频率分布男女之间差异无统计学意义(P>0.05);男性精神分裂症患者携带rs274622罕见基因型CC者一般精神病理症状分和兴奋因子分、抑郁因子分均高于常见基因型TT携带者[(46.80±13.03)VS.(32.92±7.65),(20.00±5.15)vs.(12.35±5.26),(6.60±2.16)vs.(3.99±1.72);均P<0.05];女性精神分裂症患者携带rs274622罕见基因型CC者抑郁因子分高于常见基因型TT携带者[(8.00±3.61)vs.(4.93±2.27),P<0.05];相对于TT_AA基因型组合,女性患者的抑郁因子分在CC_GG基因型组合中存在显著的统计学联合作用(CC_GG:12.00±1.00,TT_AA:5.02±2.35,β=6.96).结论:在中国汉族人群中mGluR3基因遗传多态性可能与偏执型精神分裂症的部分临床症状关联.     

精神分裂症与六种候选功能基因的关联研究

目的：探讨多巴胺D2受体基因（dopamine D2 receptor,DRD2)、多巴胺D4受体基因（DRD4）、5－羟色胺2A受体基因（5－hydroxytryptamine 2A receptor,5-HT2A),5-羟色胺6受体基因（5－HT6)、儿茶酚胺氧位甲基转移酶基因（catechol-O-methyltransferase,COMT)和多巴胺转运体基因（dopamine transferase,DAT1)多态性与精神分裂症的关系。方法：应用基因扩增片段长度多态和基因扩增的限制性片段长度多态技术，对中国汉族人群中67例精神分裂症患者与上述6种候选功能和基因扩增的限制性片段长度多态技术，对中国汉族人群中67例精神分裂症患者与上述6种候选功能基因进行遗传关联分析。结果：（1）DRD2、5－HT2A、5－HT6和KCOMT的基因型和等位基因频率在患者组和对照组中差异无显著性（P＞0．05）。（2）DRD4基因中6次重复序列等位基因、DAT1基因中480bp等位基因和480／520基因型在两组中差异有显著性，Z分别为2．03、2．05和2．05；P均小于0．05。（3）经关联分析后，仅DAT1基因的480bp等位基因的比值比为0．441，95％可信区间为0．202－0．963，并有显著性意义（Z＝2．05，P＜0．05），而DAT1的480／520基因型和DRD4和6次重复序列等位基因的比值比分别为0．128和0．123，但Z均小于1．96，无显著性意义（P＞0．05）。因此，6个功能基因中仅DAT1的480bp等位基因与精神分裂症呈负关联。结论：中国汉族人群中DAT1基因的480bp等位基因与精神分裂症间存在负关联，支持精神分裂症的多巴胺假说。     

维生素D受体基因多态性与乙型肝炎病毒感染的关联研究

目的探讨中国汉族人群维生素D受体（vitamin D receptor，VDR）基因多态性是否与乙型肝炎病毒（hepatitis B virus，HBV）感染结局相关联。方法以184例慢性乙肝患者和205名无症状HBV携带者为研究对象，收集外周血，提取基因组DNA，应用聚合酶链反应．限制性片段长度多态性（polymerase chain reaction-restriction fragmentlength polymorphism，PCIR-RFLP）方法，分析VDR基因第2外显子Fok Ⅰ位点、第9外显子Taq Ⅰ位点的多态性分布。结果单因素分析结果显示Fok Ⅰ位点FF基因型在慢性乙肝组的频率44．6％显著高于无症状HBV携带组的31．7％（P〈0．05）。经多因素非条件Logistic回归分析调整混杂作用后，结果仍然显示FF基因型在慢性乙肝组与无症状HBV携带组之间的差异存在统计学意义（OR=1．95，P〈0．05）。FokⅠ位点与TapⅠ位点组成的FT单倍型在慢性乙肝组的分布频率显著高于无症状HBV携带组（OR=1．45，P〈0．05），fT单倍型在慢性乙肝组的分布频率显著低于无症状HBV携带组（OR=0．72，P〈0．05）。结论维生素D受体基因多态性可能影响HBV感染的遗传易感性。     

维生素D受体基因多态性与乳腺癌的相关性

目的：研究维生素D受体基因的多态性与乳腺癌的关系。方法：收集86例乳腺癌患者及134名对照,用聚合酶链反应－限制性片段长度多态性方法,在维生素D受体基因的3’端分析了两个限制性酶切位点（ApaI及TaqI）的多态分布。结果：发现TaqI位点等位基因在两个群体间分布的差异有显著性（P＝0．0004）。进一步对基因型进行分析发现,Tt、tt基因型与乳腺癌相关。而ApaI位点两等位基因未发现在两群体中存在差异。对ApaI及TaqI两座位的单体型进行分析,发现tA间存在连锁不平衡。在两群体中分析单体型的分布发现tA在病例中的比例明显高于对照人群,提示tA单体型与乳腺癌相关。两个位点等位基因及单体型与临床指标的分析均未发现阳性结果。结论：维生素D受体基因的多态怀与乳腺癌有关,提示维生素D受体基因与乳腺癌有关。     

Association between three functional polymorphisms of dopamine D2 receptor gene and tardive dyskinesia in schizophrenia

The dopamine D2 receptor (DRD2) gene is considered one of the candidate genes contributing to the development of tardive dyskinesia (TD). In the present study, we investigated the genetic association between three functional polymorphisms (Ser311Cys, ?141C Ins/Del and TaqI A) in the DRD2 gene and TD (200 patients with schizophrenia: 44 with TD and 156 without TD). No significant difference in the allelic and genotypic distribution between patients with TD and those without TD was observed. However, we found a slightly significant association between the ?141C Ins/Del polymorphism and the total Abnormal Involuntary Movement Scale (AIMS) score (P = 0.037). The significant association between the ?141C Ins/Del polymorphism and the total AIMS score did not remain after the regression analysis was taken into account (P = 0.14). Our results suggest that that three functional polymorphisms in DRD2 may not play a major role in the occurrence of TD. © 2001 Wiley‐Liss, Inc.     

No association of a functional polymorphism in the dopamine D2 receptor promoter region with bipolar or unipolar affective disorders

The dopaminergic system, along with the serotonergic and noradrenergic systems, has been implicated in the etiology of mood disorders. An association study of a functional variant in the promoter region of the dopamine D2 receptor (DRD2) with bipolar affective disorder I or unipolar major affective disorders was performed. Variable expression of the DRD2 gene in vitro has been shown with this promoter polymorphism. One hundred and thirty-one unrelated bipolar patients, 128 unrelated unipolar patients, and 262 controls were used in the study. There were no significant differences in DRD2 allele or genotype frequencies between the affective disorder and control groups. These results do not support a major role for the DRD2 gene in the etiology of either bipolar or unipolar affective disorders. Am. J. Med. Genet. (Neuropsychiatr. Genet.) 81:385–387, 1998. © 1998 Wiley-Liss, Inc.     

Association study of schizophrenia and the dopamine D3 receptor gene locus in two independent samples

Using a case-control design, an association of schizophrenia with the dopamine D3 receptor gene (D3RG) locus was investigated. Initial analysis of pooled results from published studies revealed a significant excess of individuals homozygous for either allele among the patients. The association was next tested in two cohorts ascertained independently at Pittsburgh, Pennsylvania and at Houston, Texas. The Pittsburgh sample was comprised of patients with schizophrenia (DSM-III-R) (n = 130). The controls belonged to two groups: adults screened for the absence of substance abuse or major psychiatric illness (n = 128), and neonates (n = 160). Multivariate analysis suggested an association with allele 1 of the biallelic D3RG polymorphism in comparison with the adult, but not the neonatal, controls. The association was most marked among Caucasian patients with a family history of schizophrenia (odds ratio 13.69, confidence intervals 1.80, 104.30). Survival analysis suggested an earlier age of onset among male patients homozygous for allele 2. The Houston cohort included Caucasian patients with schizophrenia or schizoaffective disorder (DSM-III-R criteria, n = 50), and normal controls matched for gender (n = 51). In this group, no significant associations were noted among all the patients or among subgroups of patients based on family history or age of onset. Possible reasons for the discordant results are discussed. © 1996 Wiley-Liss, Inc.     

Association study between the dopamine D4 receptor gene and schizophrenia

The dopamine D4 receptor is of major interest in schizophrenia research due to its high affinity for the atypical neuroleptic cloza-pine and a high degree of variability in the receptor gene (DRD4). Although several genetic linkage analyses performed on schizophrenia multiplex families from different regions of the world have either excluded or failed to prove that DRD4 is a major genetic factor for the development of schizophrenia, analyses for moderate predisposing effects are still of significant interest. We performed a study examining differences in allele frequencies of 4 different DRD4 polymorphisms in schizophrenia patients and age, sex, and ethnic origin matched controls. None of these 4 polymorphisms showed evidence for genetic association with schizophrenia, although a trend towards excess of the allele with 7 repeats in the (48)_n bp exon III polymorphism was observed. Complexities in the DRD4 genetic investigation and further analytic approaches are discussed. © 1995 Wiley-Liss, Inc.     

No association between a promoter dopamine D4 receptor gene variant and schizophrenia

The dopamine D₄ receptor has been implicated in the pathogenesis of schizophrenia. An association between a putative functional promoter polymorphism (?521C/T) in the dopamine D₄ receptor gene (DRD4) and schizophrenia was recently reported. In the present study, patients with schizophrenia (n = 132) and control subjects (n = 388) were analyzed with respect to the DRD4 ? 521C/T polymorphism. No significant case control differences emerged. The present results do not support a major role for DRD4 in the etiology of schizophrenia among Caucasians from Sweden. © 2001 Wiley‐Liss, Inc.     

Further evidence of no association between Ser9Gly polymorphism of dopamine D3 receptor gene and schizophrenia

Dopamine D3 receptor (DRD3) was demonstrated to have important implications in schizophrenia, because it binds antipsychotic drugs and is abundant in the limbic system of the brain. Several groups attempted to find an association between a serine-to-glycine polymorphism at codon 9 of the DRD3 gene (Ser9Gly) and schizophrenia; however, the results were inconsistent. We conducted a case-control association study in Han Chinese schizophrenic patients from Taiwan, to examine the relationship of this serine-to-glycine polymorphism and schizophrenia. We noted no significant differences of genotype distribution, allele frequencies, or homozygosity proportion of this polymorphism between schizophrenic patients (N = 178) and controls (N = 100). When patients were divided according to sex, or presence or absence of family history, the differences were still not significant. Our study does not support the contention that the Ser9Gly polymorphism of the DRD3 gene plays a major role in schizophrenia. Am. J. Med. Genet. 74:40–43, 1997. © 1997 Wiley-Liss, Inc.     

Association of dopamine receptor D5 gene polymorphism with peculiarities of voluntary attention in schizophrenic patients and their relatives

We studied the relationship between DRD5 gene polymorphism presented by microsatellites with cognitive signs in 152 schizophrenic patients, 81 mentally healthy relatives, and 125 mentally healthy control individuals. An association was found between DRD5 polymorphism with efficiency of visual voluntary attention in patients (p=0.02) and their relatives (p=0.006). Carriers of two copies of the 148-b.p. allele were characterized by low efficiency of attention. __________ Translated from Byulleten’ Eksperimental’noi Biologii i Meditsiny, Vol. 145, No. 1, pp. 71–73, January, 2008     

Association study of schizophrenia with dopamine D3 receptor gene polymorphisms: Probable effects of family history of schizophrenia?

Using a case-control design, a reported association of schizophrenia with homozygosity at the dopamine D3 receptor gene locus was investigated in a group of patients (n = 53), with schizophrenia (DSM-III-R), and psychiatrically normal controls (n = 61), matched for ethnicity and area of residence. No significant differences in the distribution of alleles or genotypes between the two groups could be deteched. However, among patients with a family history of schizophrenia, as compared to controls without such family history, an association with allele 1 at this locus was noted (Odds ratio 12.4, C.I. 1.61, 96.35). © 1993 Wiley-Liss, Inc.